The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tsoriev T.T.

The National Research Center for Endocrinology, Moscow, Russia

Belaia Zh.E.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva

Osteo-articular structural impairments in acromegaly somatostatin receptor expression in adrenocortical carcinomas

Authors:

Tsoriev T.T., Belaia Zh.E.

More about the authors

Journal: Problems of Endocrinology. 2018;64(2): 121‑129

DOI: 10.14341/probl9305

Views: 2357

Downloaded: 60

Download PDF (RU)
Contact the author
Table of contents

OSTEO-ARTICULAR STRUCTURAL IMPAIRMENTS IN ACROMEGALY SOMATOSTATIN RECEPTOR EXPRESSION IN ADRENOCORTICAL CARCINOMAS
OSTEO-ARTICULAR STRUCTURAL IMPAIRMENTS IN ACROMEGALY SOMATOSTATIN RECEPTOR EXPRESSION IN ADRENOCORTICAL CARCINOMAS

To cite this article:

Tsoriev TT, Belaia ZhE. Osteo-articular structural impairments in acromegaly somatostatin receptor expression in adrenocortical carcinomas. Problems of Endocrinology. 2018;64(2):121‑129. (In Russ.)
https://doi.org/10.14341/probl9305

МСФ на ЯМ
Close metadata
Recommended articles:
Orga­nization of a Seco­ndary Fracture Prevention System. Expert group reco­mmendations. Russian Journal of Preventive Medi­cine. 2024;(8):26-31
Clinical consequences of the sarcopenic obesity. Part 2. Cardiovascular diseases and osteoporosis. Russian Journal of Preventive Medi­cine. 2024;(9):60-66
Feasibility of application in the practice of dental diseases of meta­bolic changes in bone tissue in examination of patients with chro­nic kidney disease. Russian Journal of Stomatology. 2024;(3):16-22
Liver and bone in tandem: osteopenia as an inevitable companion to non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):40-50

Elevated serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in patients with acromegaly result in intensified bone turnover, as evidenced by increased levels of bone remodeling markers and higher risk of low-traumatic vertebral fractures. However, it was repeatedly observed that bone mineral density (BMD) is normal or even increased in patients with acromegaly (including the active stage of the disease). Increased secretion of GH/IGF-1 causes structural changes in the vertebrae and peripheral joints (osteophyte formation and cartilage hypertrophy), resulting in pain and various deformities of the articular system. These changes are known under the common name «acromegalic arthropathy». It is quite specific complication of the disease. Skeletal complications of acromegaly can persist even after radical treatment, i.e., their course and progression, presumably, do not necessarily depend on the remission level of the underlying disease. This review summarizes the current understanding of the pathophysiology, clinical presentation, diagnosis, and treatment of osteo-articular complications of acromegaly.

Keywords:

acromegaly
osteoporosis
low-traumatic fractures
trabecular bone
acromegalic arthropathy

Authors:

Tsoriev T.T.

The National Research Center for Endocrinology, Moscow, Russia

Belaia Zh.E.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva

List of references:

  1. Dedov II, Mel’nichenko GA, editors. Endocrinology. Russian clinical guidelines. Moscow: GEOTAR-Media; 2016. (In Russ.)
  2. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-152. doi:10.1210/er.2002-0022
  3. Mazziotti G, Bilezikian J, Canalis E, et al. New understanding and treatments for osteoporosis. Endocrine. 2012;41(1):58-69. doi:10.1007/s12020-011-9570-2
  4. Grebennikova TA, Belaya ZhE, Rozhinskaya LY, Mel’nichenko GA, Dedov II. Epigenetic aspects of osteoporosis. Vestnik Rossiyskoy Akademii Meditsinskikh Nauk. 2015;70(5):541-548. (In Russ.) doi: 10.15690/vramn.v70.i5.1440
  5. Dedov II, Mel’nichenko GA, Belaya ZhE, Rozhinskaya LY. Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX—XXI centuries. Problemy Endokrinologii. 2011;57(1):35-45. (In Russ.) doi: 10.14341/probl201157135-45
  6. Wassenaar MJ, Biermasz NR, van Duinen N, et al. High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with longterm cure of acromegaly: a case-control study. Eur J Endocrinol. 2009;160(3):357-365. doi:10.1530/EJE-08-0845
  7. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev.2008;29(5):535-559. doi:10.1210/er.2007-0036
  8. Lanyon L, Armstrong V, Ong D, Zaman G, Price J. Is estrogen receptor alpha key to controlling bones’ resistance to fracture? J Endocrinol. 2004;182(2):183-191. doi:10.1677/joe.0.1820183
  9. Schousboe JT, Shepherd JA, Bilezikian JP, et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455-466. doi:10.1016/j.jocd.2013.08.004
  10. Tsoriev TT, Belaya ZhE, Mel’nichenko GA. Trabecular bone score — a non-invasive analytical method to evaluate bone quality based on routine dual-energy absorptiometry. Perspectives of its use in clinical practice. Almanaс of clinical medicine. 2016;44(4):462-476. (In Russ.) doi: 10.18786/2072-0505-2016-44-4-462-476
  11. Melnichenko GA, Belaya ZhE, Rozhinskaya LY, et al. Summary of clinical guidelines for the diagnosis and treatment of osteoporosis of the Russian Association of Endocrinologists. Osteoporosis and osteopathy. 2016;19(3):28-36. (In Russ.)
  12. Longobardi S, Di Somma C, Di Rella F, et al. Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest. 1998;21(10):688-693. doi:10.1007/bf03350799
  13. Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res. 2005;20(10):1837-1844. doi:10.1359/JBMR.050603
  14. Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab. 2008;93(12):4649-4655. doi:10.1210/jc.2008-0791
  15. Scillitani A, Chiodini I, Carnevale V, et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res. 1997;12(10):1729-1736. doi:10.1359/jbmr.1997.12.10.1729
  16. Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab. 2013;98(8):3402-3410. doi:10.1210/jc.2013-1460
  17. Matsuyama J, Eshima N, Fukunaga T, et al. Various risks of osteoporosis in patients with pituitary adenomas. J Bone Miner Metab. 2003;21(2):91-97. doi:10.1007/s007740300015
  18. Bolanowski M, Daroszewski J, Medra M, et al. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab. 2006;24(1):72-78. doi:10.1007/s00774-005-0649-9
  19. Ueland T, Fougner SL, Godang K, et al. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol. 2006;155(5):709-715. doi:10.1530/eje.1.02285
  20. Romijn JA. Acromegalic arthropathy: current perspectives. Endocrine. 2013;43(2):245-246. doi:10.1007/s12020-012-9781-1
  21. Madeira M, Neto LV, de Paula Paranhos Neto F, et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2013;98(4):1734-1741. doi:10.1210/jc.2012-4073
  22. Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2015;100(2):384-394. doi:10.1210/jc.2014-2937
  23. Poteshkin YE, Pronin VS, Mel’nichenko GA, et al. Growth hormone and IGF-1 effects on articular and skeletal system in acromegaly. Relevant endocrinology. 2015;(10):2. (In Russ.) doi: 10.18508/endo3539
  24. Diamond T, Nery L, Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med. 1989;111(7):567-573. doi:10.7326/0003-4819-111-7-567
  25. Lesse GP, Fraser WD, Farquharson R, et al. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf). 1998;48(1):59-65. doi:10.1046/j.1365-2265.1998.00349.x
  26. Padova G, Borzi G, Incorvaia L, et al. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab. 2011;8(3):37-43.
  27. Griffith JF, Genant HK. New advances in imaging osteoporosis and its complications. Endocrine.2012;42(1):39-51. doi:10.1007/s12020-012-9691-2
  28. Ulivieri FM, Silva BC, Sardanelli F, et al. Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine. 2014;47(2):435-448. doi:10.1007/s12020-014-0280-4
  29. Marazuela M, Astigarraga B, Tabuenca MJ, et al. Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int. 1993;52(6):419-421. doi:10.1007/bf00571329
  30. Tsoriev TT, Grebennikova TA, Belaya ZE, et al. Bone turnover markers and serum sclerostin levels in patients with acromegaly. In: Kanis JA, Cosman F, editors. Osteoporos Int (Abstract Book). 27 Suppl 1. WCO-IOF-ESCEO 2016: Proceedings of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; 2016 Apr 14-17; Malaga, Spain. Berlin: Springer; 2016;182-183.
  31. Kamenicky P, Mazziotti G, Lombes M, et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014;35(2):234-281. doi:10.1210/er.2013-1071
  32. Grebennikova TA, Belaya ZhE, Tsoriev TT, et al. The endocrine function of the bone tissue. Osteoporosis and osteopathy. 2015;18(1):28-37. (In Russ.) doi: 10.14341/osteo2015128-37
  33. Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int. 1997;7(3):226-230. doi:10.1007/bf01622293
  34. Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly – a potential beneficial effect of growth hormone. Osteoporos Int. 2004;15(2):155-159. doi:10.1007/s00198-003-1531-z
  35. Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985—1989. J Bone Miner Res. 1992;7(2):221-227. doi:10.1002/jbmr.5650070214
  36. Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol. 2011;164(4):475-483. doi:10.1530/EJE-10-1005
  37. Brzana J, Yedinak CG, Hameed N, et al. FRAX score in acromegaly: does it tell the whole story? Clin Endocrinol (Oxf). 2014;80(4):614-616. doi:10.1111/cen.12262
  38. Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite longterm biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab. 2013;98(12):4808-4815. doi:10.1210/jc.2013-2695
  39. Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest. 2003;26(12):1242-1247. doi:10.1007/bf03349164
  40. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294-302. doi:10.1007/s11102-012-0420-x
  41. Lindsay R, Pack S, Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int. 2005;16(3):306-312. doi:10.1007/s00198-004-1691-5
  42. Jalava T, Sarna S, Pylkkänen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res. 2003;18(7):1254-1260. doi:10.1359/jbmr.2003.18.7.1254
  43. Cauley JA, Hochberg MC, Lui LY, et al. Long-term risk of incident vertebral fractures. JAMA. 2007;298(23):2761-2767. doi:10.1001/jama.298.23.2761
  44. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000;15(7):1384-1392. doi:10.1359/jbmr.2000.15.7.1384
  45. Mazziotti G, Baracca M, Doga M, et al. Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. Eur J Endocrinol. 2012;167(6):865-872. doi:10.1530/EJE-12-0566
  46. Diacinti D, Guglielmi G. Vertebral morphometry. Radiol Clin North Am. 2010;48(3):561-575. doi:10.1016/j.rcl.2010.02.018
  47. Vosse D, Heijckmann C, Landewé R, et al. Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology (Oxford). 2007;46(11):1667-1671. doi:10.1093/rheumatology/kem135
  48. Schousboe JT, Vokes T, Broy SB, et al. Vertebral Fracture Assessment: the 2007 ISCD Official Positions. J Clin Densitom. 2008;11(1):92-108. doi:10.1016/j.jocd.2007.12.008
  49. Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res. 2006;21(4):520-528. doi:10.1359/jbmr.060112
  50. Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000;85(7):2476-2482. doi:10.1210/jcem.85.7.6699
  51. Mazziotti G, Porcelli T, Bianchi A, et al. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol. 2010;163(1):15-20. doi:10.1530/EJE-10-0125
  52. Mazziotti G, Mormando M, Cristiano A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol. 2014;170(6):893-899. doi:10.1530/EJE-14-0097
  53. Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf). 1999;51(5):611-618. doi:10.1046/j.1365-2265.1999.00851.x
  54. Dieppe PA. Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Osteoarthritis Cartilage. 1995;3(2):73-77. doi:10.1016/s1063-4584(05)80040-8
  55. Altman RD, Hochberg M, Murphy WAJr, et al. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage. 1995;3 Suppl A:3-70.
  56. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494-502. doi:10.1136/ard.16.4.494
  57. Wassenaar MJ, Biermasz NR, Bijsterbosch J, et al. Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis. 2011;70(2):320-325. doi:10.1136/ard.2010.131698
  58. Claessen KM, Kloppenburg M, Kroon HM, et al. Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Horm IGF Res. 2013;23(5):159-164. doi:10.1016/j.ghir.2013.05.003
  59. Biermasz NR, van’t Klooster KR, Wassenaar MJ, et al. Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur J Endocrinol. 2012;166(3):407-413. doi:10.1530/EJE-11-0795
  60. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-1840. doi:10.1186/1471-2474-13-168
  61. Bellamy N, Campbell J, Haraoui B, et al. Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage. 2002;10(11):863-869. doi:10.1053/joca.2002.0838
  62. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039-1049. doi:10.1002/art.1780290816
  63. Kropf LL, Madeira M, Vieira NL, et al. Functional evaluation of the joints in acromegalic patients and associated factors. Clin Rheumatol. 2013;32(7):991-998. doi:10.1007/s10067-013-2219-1
  64. Dons RF, Rosselet P, Pastakia B, et al. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf). 1988;28(5):515-524. doi:10.1111/j.1365-2265.1988.tb03686.x
  65. Biermasz NR, Wassenaar MJ, van der Klaauw AA, et al. Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. J Clin Endocrinol Metab. 2009;94(7):2374-2379. doi:10.1210/jc.2008-2393
  66. Wassenaar MJ, Biermasz NR, Pereira AM, et al. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab. 2009;94(12):4671-4678. doi:10.1210/jc.2009-1172
  67. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89(6):2789-2796. doi:10.1210/jc.2003-032041
  68. Scarpa R, De Brasi D, Pivonello R, et al. Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab. 2004;89(2):598-603. doi:10.1210/jc.2003-031283
  69. Claessen KM, Ramautar SR, Pereira AM, et al. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol. 2012;167(2):235-244. doi:10.1530/EJE-12-0147
  70. van Thiel SW, Bax JJ, Biermasz NR, et al. Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol. 2005;153(2):231-238. doi:10.1530/eje.1.01955
  71. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853-3859. doi:10.1210/jc.2008-0669
  72. Örük G, Tarhan F, Argın M, et al. Is every joint symptom related to acromegaly? Endocrine. 2013;43(2):404-411. doi:10.1007/s12020-012-9770-4

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.